ArticleBMC cancer2025
Immediate risk and 5-year cumulative risk of high-grade cervical lesions in high-risk HPV-positive patients with minor cytological abnormalities: a retrospective single-center study in China.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Additional Diagnostic Yield of Endocervical Curettage in Type 3 Transformation Zone for High-Grade Cervical Lesions: A Retrospective Analysis by Human Papillomavirus Genotype.Diagnostics (Basel, Switzerland) · 2026Article
- Cytology-Biopsy Concordance in High-Risk Human Papillomavirus-Positive Women with Abnormal Cytology Findings: Menopause-Stratified Analysis.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough minor cytological abnormalities predict a low risk of high-grade lesions, their high reporting rates lead to a considerable number of high-grade lesion cases. We carried out this study to analyze the immediate risk and 5-year cumulative risk of high-grade cervical lesions in high-risk human papillomavirus (Hr-HPV)-positive patients with minor cytological abnormalities and to investigate the clinical significance of minor cytological abnormalities during follow-up in our single-center.
methodsA total of 1892 patients with positive Hr-HPV, cytology result of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL) and also underwent colposcopy and biopsy were selected to analyze the immediate risk of high-grade cervical lesions. Besides, a total of 832 patients with baseline histological results of CIN1 or below and 5-year follow-up data available were further used to analyze the 5-year cumulative risk of high-grade cervical lesions.
resultsThe immediate incidence rates of CIN3 + in the ASC-US and LSIL groups were 6.27% (63/1005) and 5.64% (50/887), respectively. When CIN3 + was used as the study endpoint, the multivariate logistic regression analysis indicated that there was no significant difference in either the immediate risk or the 5-year cumulative risk of CIN3 + between the ASC-US and LSIL groups.
conclusionsIn summary, since both the immediate and 5-year follow-up risks for CIN3 + were similar in patients with ASC-US and LSIL, routine follow-up should be performed in minor cytological abnormalities, regardless of whether the cytology result is ASC-US or LSIL. Through the risk assessment of Hr-HPV and cytology combined screening, the 2019 ASCCP guidelines were suitable for cervical cancer screening at our single center.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.